Company intelligence / Profile preview

EcoPhage

Ownership: Private
Development stage: Commercial

Overview

EcoPhage has developed a proprietary phage-based technology platform to create sustainable biopesticides for controlling bacterial diseases in crops. Their lead product, GoldenEco, is being commercialized in Brazil through a distribution agreement with Maian. Field results indicate superior performance compared to conventional pesticides, with added benefits of higher yield and better quality crops. The company’s solutions are positioned as alternatives to copper and antibiotic treatments that face resistance issues and regulatory pressure.

Therapeutic areas: Infectious Diseases
Modalities: Microbial therapyLive biotherapeutic product therapy
Industry: Non-Drug Biotech

Drug pipeline

1 asset

GoldenEco

Commercial

Indications: Bacterial diseases in tomatoes and peppers

Partnerships

Maian Ltda. (distribution partner for Brazil)Bayer-Trendlines Ag Innovation Fund

Beyond the preview

Go deeper on EcoPhage.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EcoPhage.

Explore the full profile